Ezogabine
- Generic Name
- Ezogabine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C16H18FN3O2
- CAS Number
- 150812-12-7
- Unique Ingredient Identifier
- 12G01I6BBU
- Background
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine.
- Indication
Adjuvant treatment of partial-onset seizures.
- Associated Conditions
- Refractory Partial Onset Seizures
- Associated Therapies
- -
The efficacy and cerebral mechanism of intradermal acupuncture for major depressive disorder
Depression research references cover antidepressant efficacy, SSRI discontinuation challenges, exercise and acupuncture treatments, neuroimaging studies, and the role of reward circuitry in depressive behaviors.
Novel Epilepsy Drug Shows Breakthrough Safety Profile in Clinical Trials
Biohaven presents expanded safety data from BHV-7000 multiple-dose studies at AES 2024, showing excellent tolerability without CNS adverse effects. Social media insights reveal unmet needs in epilepsy patients, and nonclinical data includes BHV-7000's effects on KCNQ2 variants. Biohaven remains committed to developing novel, efficacious, and well-tolerated therapies for epilepsy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath